Kintor is a pharmaceutical research company.
Kintor founded in Suzhou in 2009, focusing on prostate cancer, breast cancer and liver cancer which account for more than 50% of the global cancer population and lack of effective treatment method. They have a product pipeline built on proprietary R&D and licensing arrangement, aiming to provide the best treatment plans for huge unmet patient needs. They focus on developing a full R&D and commercialization platform for “best-in-class” and “first-in-class” novel drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 12, 2018 | Series C | $44M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
China Orient Asset Management (International) Holding | — | Series C |